-
公开(公告)号：KR1020140086213A
公开(公告)日：2014-07-08
申请号：KR1020120156419
申请日：2012-12-28
Applicant: 한국식품연구원
IPC: A61K31/519 , A61K31/407 , A61P3/04
CPC classification number: A61K31/519 , A23L33/10 , A61K31/407 , Y10S514/866 , Y10S514/886
Abstract: The present invention relates to a composition for treating obesity-induced inflammation, wherein the composition contains evodiamine as an active ingredient. The composition of the present invention induces the expression of adiponectin and decreases the expression of IL-6 and MCP-1 which are involved in obesity-mediated inflammation reaction so that obesity-induced inflammation can be prevented and treated.
Abstract translation: 本发明涉及一种用于治疗肥胖症的炎症的组合物，其中该组合物含有作为活性成分的吴茱萸碱。 本发明的组合物诱导脂联素的表达并降低参与肥胖介导的炎症反应的IL-6和MCP-1的表达，从而可以预防和治疗肥胖诱发的炎症。
-
公开(公告)号：KR1020140086210A
公开(公告)日：2014-07-08
申请号：KR1020120156408
申请日：2012-12-28
Applicant: 한국식품연구원
IPC: A61K31/47 , A61K31/435 , A61P3/04 , A61P29/00
CPC classification number: A61K31/4741 , A23L33/10 , A61K31/4748 , Y10S514/866 , Y10S514/886 , Y10S514/909
Abstract: The present invention relates to a composition for treating obesity-induced inflammation, wherein the composition contains tetrandrine as an active ingredient. The composition of the present invention induces the expression of adiponectin and decreases the expression of IL-6 and MCP-1 which are involved in obesity-mediated inflammation reaction so that obesity-induced inflammation can be prevented and treated.
Abstract translation: 本发明涉及一种用于治疗肥胖症引起的炎症的组合物，其中该组合物含有四片丹宁作为活性成分。 本发明的组合物诱导脂联素的表达并降低参与肥胖介导的炎症反应的IL-6和MCP-1的表达，从而可以预防和治疗肥胖诱发的炎症。
-
公开(公告)号：KR101349089B1
公开(公告)日：2014-01-10
申请号：KR1020120021489
申请日：2012-02-29
Applicant: 한국식품연구원
IPC: A61K31/357 , A61K31/35 , A61K31/352 , A61P3/04
Abstract: 본 발명은 바바치닌 A를 유효성분으로 함유하는 비만 또는 지질 관련 대사성 질환의 예방 및 치료용 약학적 조성물과 건강기능식품에 관한 것으로 본 발명에 따른 바바치닌 A는 지방세포분화 저해 효과가 우수하므로, 이를 유효성분으로 함유하는 비만 또는 지질 관련 대사성 질환의 예방 및 치료용 약학적 조성물과 건강기능식품으로 사용할 수 있다.
-
公开(公告)号：KR101327938B1
公开(公告)日：2013-11-14
申请号：KR1020110037694
申请日：2011-04-22
Applicant: 한국식품연구원
IPC: A61K31/215 , A61K31/21 , A61K9/48 , A61P3/04
Abstract: 본 발명은 메틸 카페이트를 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 약학적 조성물과 건강기능식품에 관한 것이다. 상기 조성물 또는 건강기능식품은 지방세포분화 저해 효능이 우수하다.
-
公开(公告)号：KR1020130099754A
公开(公告)日：2013-09-06
申请号：KR1020120021490
申请日：2012-02-29
Applicant: 한국식품연구원
IPC: A61K31/122 , A61K9/16 , A61K9/20 , A61P3/04
Abstract: PURPOSE: A composition containing deoxyshikonin for preventing and treating obesity or lipid metabolic disorders is provided to effectively suppress adipocyte differentiation. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity or lipid metabolic disorders contains deoxyshikonin as an active ingredient. The metabolic disorders are selected among diabetes, hyperlipidemia, fatty liver, arteriosclerosis, hypertension, cardiovascular disease, and metabolic syndrome. Deoxyshikonin suppresses adipocyte differentiation. A health food for preventing obesity or lipid-related metabolic disorders or alleviating symptoms thereof contains deoxyshikonin as an active ingredient. [Reference numerals] (AA) Neutral lipid (absorbance); (BB) Normal; (CC) Control group; (DD) Deoxyshikonin
Abstract translation: 目的：提供含有去氧喜草素预防和治疗肥胖症或脂质代谢紊乱的组合物，以有效抑制脂肪细胞分化。 构成：用于预防和治疗肥胖或脂质代谢紊乱的药物组合物含有脱氧喜树碱作为活性成分。 代谢紊乱选自糖尿病，高脂血症，脂肪肝，动脉硬化，高血压，心血管疾病和代谢综合征。 去氧喜树碱抑制脂肪细胞分化。 用于预防肥胖或与脂质有关的代谢紊乱或减轻其症状的保健食品含有脱氧喜树碱作为活性成分。 （AA）中性脂质（吸光度）; （BB）正常; （CC）对照组; （DD）Deoxyshikonin
-
Patent Agency Ranking
公开(公告)号：KR1020130099753A
公开(公告)日：2013-09-06
申请号：KR1020120021489
申请日：2012-02-29
Applicant: 한국식품연구원
IPC: A61K31/357 , A61K31/35 , A61K31/352 , A61P3/04
Abstract: PURPOSE: A composition containing bavachinin A for preventing and treating obesity or lipid metabolic disorders is provided to effectively suppress adipocyte differentiation. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity or lipid metabolic disorders contains bavachinin A as an active ingredient. The lipid metabolic disorder is selected among diabetes, hyperlipidemia, fatty liver, arteriosclerosis, hypertension, cardiovascular disease, and metabolic syndrome. Bavachinin A suppresses adipocyte differentiation. A health food for preventing obesity or lipid metabolic disorders contains bavachinin A as an active ingredient. [Reference numerals] (AA) Neutral lipid (absorbance); (BB) Normal; (CC) Control group; (DD) Bavachinin A
Abstract translation: 目的：提供含有巴伐他丁A用于预防和治疗肥胖症或脂质代谢紊乱的组合物以有效抑制脂肪细胞分化。 构成：用于预防和治疗肥胖或脂质代谢紊乱的药物组合物含有巴伐他丁作为活性成分。 脂代谢紊乱选自糖尿病，高脂血症，脂肪肝，动脉硬化，高血压，心血管疾病和代谢综合征。 巴伐他汀A抑制脂肪细胞分化。 用于预防肥胖或脂质代谢紊乱的保健食品含有巴伐他丁A作为活性成分。 （AA）中性脂质（吸光度）; （BB）正常; （CC）对照组; （DD）巴伐他汀A
-
公开(公告)号：KR1020130098759A
公开(公告)日：2013-09-05
申请号：KR1020120020537
申请日：2012-02-28
Applicant: 한국식품연구원
CPC classification number: Y02A90/26
Abstract: PURPOSE: A method for diagnosing aging is provided to diagnose aging and related diseases by measuring a change in the concentration of a specific metabolite in a liver extract and to treat aging-related diseases. CONSTITUTION: A method for diagnosing aging comprises the steps of: measuring the concentration of one selected among a metabolite group including 3-methylglutarylcarnitine, isovalerylcarnitine, palmitoylcarnitine, iobutyrylcarnitine, hypoxanthine, patothenic acid, lysophosphatidylcholine(C18:0) and lysophosphatidylcholine(C22:6); measuring the concentration of one selected among the metabolite group; and determining aging when the primarily measured concentration is higher than the secondarily measured concentration.
Abstract translation: 目的：通过测量肝脏提取物中特定代谢物浓度的变化和治疗老化相关疾病，提供诊断衰老的方法诊断衰老及相关疾病。 构成：用于诊断老化的方法包括以下步骤：测量选自包括3-甲基戊二酰肉碱，异戊基肉毒碱，棕榈酰肉碱，异丁酸肉碱，次黄嘌呤，氨基苯甲酸，溶血磷脂酰胆碱（C18：0）和溶血磷脂酰胆碱（C22：6） ）; 测定代谢组中选出的1种浓度; 并且当主要测量的浓度高于二次测量的浓度时，确定老化。
-
公开(公告)号：KR1020130001510A
公开(公告)日：2013-01-04
申请号：KR1020110062313
申请日：2011-06-27
IPC: A61K36/752 , A61P3/10 , A61P3/00
CPC classification number: A61K36/752 , A23L33/105 , A23V2200/328 , A23V2250/21 , A61K2236/331 , Y10S514/866
Abstract: PURPOSE: An anti-diabetic composition containing citron peel extract and a method for preparing the same are provided to reduce blood glucose and to improve anti-diabetic effect. CONSTITUTION: An anti-diabetic pharmaceutical composition contains citron peel extract as an active ingredient. The citron peel extract is prepared through hot water extraction using an organic solvent. The organic solvent is phenoxy ethanol, propyl paraben, benzophenone, or ethanol. The concentration of the organic solvent is 400-1200 ug/ml. The pharmaceutical composition is manufactured in the form of a powder, granules, a capsule, a suspension, an emulsion, a syrup, or an aerosol. An anti-diabetic food composition contains the extract as an active ingredient. [Reference numerals] (AA) 2NBDG-absorption; (BB) Normal group; (CC,EE) Flesh; (DD,FF) Peel; (GG) Positive control group; (HH) Negative control group; (II) Ethanol; (JJ) Water
Abstract translation: 目的：提供含有柚皮提取物的抗糖尿病药物组合物及其制备方法，以降低血糖并改善抗糖尿病作用。 构成：抗糖尿病药物组合物含有柚皮提取物作为活性成分。 柚皮提取物通过使用有机溶剂的热水提取制备。 有机溶剂是苯氧基乙醇，对羟基苯甲酸丙酯，二苯甲酮或乙醇。 有机溶剂的浓度为400-1200ug / ml。 药物组合物以粉末，颗粒，胶囊，悬浮液，乳剂，糖浆或气雾剂的形式制备。 抗糖尿病食品组合物含有提取物作为活性成分。 （标号）（AA）2NBDG吸收; （BB）正常组; （CC，EE）肉; （DD，FF）去皮; （GG）阳性对照组; （HH）阴性对照组; （二）乙醇; （JJ）水
-
49.发明公开
公开(公告)号：KR1020120061018A
公开(公告)日：2012-06-12
申请号：KR1020100109058
申请日：2010-11-04
Applicant: 한국식품연구원
Abstract: PURPOSE: A pharmaceutical composition and health functional food containing p-xyleneselenocyanate are provided to prevent and treat obesity and lipid-related metabolic disorders. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity and lipid-related metabolic disorders contains 0.1-50 wt% of p-xylene selenocyanate as an active ingreedient. The metabolic diseases include diabetes, hyperlipidemia, fatty liver, artheriosclerosis, hypertension, cardiovascular diseases, or a combination thereof. The composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, oral formulation of aerosol, external use formulation, suppository, or sterilized injection solution. A health functional food for preventing and relieving obesity and lipid-related metabolic disorders contains p-xylene selenocyanate as an active ingredient.
Abstract translation: 目的：提供含有对二甲苯硒异氰酸酯的药物组合物和保健功能食品，用于预防和治疗肥胖症和与脂质有关的代谢紊乱。 构成：用于预防和治疗肥胖症和与脂质有关的代谢紊乱的药物组合物含有0.1-50重量％的对二甲苯硒氰酸酯作为活性成分。 代谢疾病包括糖尿病，高脂血症，脂肪肝，神经硬化，高血压，心血管疾病或其组合。 组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，气雾剂口服制剂，外用制剂，栓剂或灭菌注射液的形式制造。 用于预防和减轻肥胖症和与脂质有关的代谢紊乱的健康功能食品含有对二甲苯硒氰酸酯作为活性成分。
-
公开(公告)号：KR1020120061016A
公开(公告)日：2012-06-12
申请号：KR1020100109049
申请日：2010-11-04
Applicant: 한국식품연구원
Abstract: PURPOSE: A pharmaceutical composition containing sulforaphane is provided to suppress adipocyte differentiation and to prevent and treat obesity and metabolic diseases. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity and lipid metabolic diseased contains 0.1-50 wt% of sulforaphane as an active ingredient. The sulforaphane includes R,S-sulforaphane, R-sulforaphane, or S-sulforaphane. The composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, aerosol, suppository, or sterilization injection solution. A health functional food for preventing and relieving obesity and lipid metabolic diseases contains sulforaphane as an active ingredient.
Abstract translation: 目的：提供含有萝卜硫素的药物组合物，以抑制脂肪细胞分化，预防和治疗肥胖症和代谢疾病。 构成：用于预防和治疗肥胖症和脂质代谢疾病的药物组合物含有0.1-50重量％的萝卜硫素作为活性成分。 萝卜硫烷包括R，S-四氢萘烷，R-萝卜硫烷或S-萝卜硫烷。 该组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，气雾剂，栓剂或灭菌注射溶液的形式制备。 用于预防和减轻肥胖和脂质代谢疾病的健康功能食品含有萝卜硫素作为活性成分。
-
-
-
-
-
-
-
-
-
Search Results
51
records
(took 0.025 seconds)
